International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 323-326 www.ijprajournal.com ISSN: 2456-4494

Application of Hydrazones in Biomedical Research

Jai Prakash*, Ajay Kumar Verma, Brijesh Kumar Saroj
Goel Institute of Pharmacy and Sciences Lucknow

Submitted: 05-05-2022 Accepted: 15-05-2022

ABSTRACT: Hydrazones provide the possibility of improving medication delivery by releasing drugs just where they are needed, including tumor tissue or thrombosis. Many scientists are working with chemical and heat catalysts in toan effort to effectively generate these hydrazones. Hydrazones are special in that they may be designed to release drugs based on the pH environment or certain functional groups of the hydrazone. A wide variety of uses makes them useful, from anti-inflammatory to cancer-killing and chelating agents. An in-depth look at how hydrazones' anticancer, anti-inflammatory, platelet-aggregation prevention, and chelating agent capabilities may be improved is presented in this review study.

Keywordshydrazones, drug delivery,toxicity, targeting, anticancer, anti-inflammatory, platelet aggregation.

INTRODUCTION

Increasingly, researchers are focusing on boosting the bioavailability of a pharmaceutical at the sick site since many treatments for many disorders need substantial quantities of medicine, which may have harmful off-site implications. Use of hydrazone linkers, which release drugs in response to specific illness physiology and surroundings, is one of the most exciting new techniques. Hydrazones are small chemical compounds with the formula R1–NHN=CH–R2. The functional groups represented by R1 and R2 are interchangeable. 3 Drugs with the R group conjugated may be released under strict supervision due to the hydrolysis reaction's ability to cleave the imine (N=C). 4 This alteration in the R group allows for a variety of uses and capabilities, including anti-inflammatory, antitumor, and antiviral applications. Figure 1 depicts the many compounds that may be formed from various functional groups. Various chemical processes may be used to alter hydrazones once the first hydrazine reaction is completed. Hydrazones are formed when aldehydes combine with compounds that start with a carbon carbonyl substituent group. The nitrogen bond contains two free electrons, enabling for interaction with other organic compounds or substitution groups. Nucleophilicity is a property of nitrogen whereas electrophilicity and nucleophilicity are both present in carbon, making carbon a very adaptable atom. This approach may be used in a number of ways to alter tissue conviction rates or modify the kinetics of drug release. 7,8 Scientists may modify the substituent groups on drugs to make them release only under certain conditions. Drug release may be controlled by manipulating the pH of the environment. Hydrazones are stable in blood because the pH is neutral. However, hydrazones may be broken to release active medications in areas with a lower pH, such as tutumorlocations or the endosomes of cells. 9 Many medications, including doxorubicin (DOX) for cancer therapy and gold nanoparticles (Au-NPs), have been connected to hydrazones because of their properties. Conjugated with hydrazone, 2 DOX has a high survival rate because of the pH-sensitive nature of the compound. 2,10,11 They may be a huge asset when it comes to Stability and effectiveness in prior studies make aromatic compounds attractive for drug loading. 12 Changing the production process of these compounds results in a wide range of additional alterations. There are several number of ways to optimize hydrazones through synthesis, and we'll go into more depth in this review.

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 323-326 www.ijprajournal.com ISSN: 2456-4494



Figure 1. Compounds derived from a hydrazone for specific targeting applications.[7] Reproduced from Li, L.; Peng, J.; Zhou, W.; et al. Potent Hydrazone Derivatives Targeting Esophageal Cancer Cells. *Eur. J. Med. Chem. 148*, 359–371. Copyright 2018. Elsevier Masson SAS. All rights reserved.

Hydrazones may be improved by using different synthesis methods.

The effectiveness of hydrazones may be manipulated in various ways, including pH settings, but little research delves into depth about how these hydrazones are generated. Because most research investigations need a large number of hydrazones toorder to be statistically significant, this early synthesis is time-consuming. Using chemical catalysts like proton donors, a hydrazone reaction may be sped up and generate a large amount of product. 12 The pKa values of catalysts may be researched for use as a proton donor to speed up the reaction process order to locate the best-performing chemical catalysts. To speed up the synthesis of hydrazones, the pKa should be closer to basic because of their protonic flexibility. A hydrazone can receive the proton employed in the carbon and nitrogen dual bond much more rapidly than if it is unable to do so. 12 Heat may also be used as a catalyst to speed up the synthesis of stable hydrazones. Different hydrazone molecules may be synthesized using heat. In experiments, it has been shown that employing higher temperatures increases the reaction time for hydrazone formation substantially while maintaining a high yield. 5 When the temperature is increased, not only does response time reduce but a more stable yield may be achieved in a shorter period ofin of time since the critical temperature is continuously monitored to ensure that it does not vary. Drug formulations rely on an understanding of the link between hydrazone creation efficiency and stability, and these studies are crucial in ensuring hydrazones can be generated more effectively so they can be tested more quickly. Using hydrazones in diverse biological applications is the focus of the remainder of this mini-review.

Applications of Hydrazones

Anti-Cancer Treatments

The acidic environment surrounding a tumor necessitates the use of pH-sensitive hydrazone linkers in the creation of a tailored medication delivery system. 11 To effectively target bone metastatic cancer, Ye et al. created a DOX-loaded micelle by coupling the hydrophobic DOX to the aqueous polyethylene glycol (PEG) polymer via a hydrazone bond. Researchers found that by creating the hydrazone connection between DOX and PEG, circulation times in the bloodstream were increased. 11,13 Dynamic light scattering was employed to examine the micelle size change as a function of pH.Doxhydrazone-PEG polymers were injected into the micelle (114nm) and tested for stability and morphological changes overthe course of four hours. As the DOX and PEG separate during micelle measurement, the increased size is caused by a broken hydrazone connection. As a result, the whole structure may split and grow, resulting in a larger overall size. It may be used to determine the pH at which the connection is broken. Themicelle size didn't vary much at pH 7.4, but it did rise greatly at pH 5.0. An invivo investigation on male nude mice with bone metastases was done to compare 5 mg/kg of the DOX implanted in the micelle with free DOX once this idea was proven. 11 After 30 days, the tumour volume in the treated rats with the micelle was considerably smaller than in the mouse who received a placebo. Micelle-treated mice had a 40 percent higher chance of surviving 50 days than free DOX mice, which had a 0 percent chance of surviving after only 40 days. 11 In addition, the MTTassay was used to examine the drug's toxicity, and the DOX reduced toxicity in tumor-bearing animals. As a whole, the DOX/hydrazone delivery system is more cost-effective and efficient. For the PEG coating, DOX has been linked by hydrazone linkage to a nontoxic, nanoconjugate platforms polymeric acid (PMLA). 13PEG contains a fluorescent protein for tracking and imaging and was used to reduce RES absorption. Researchers were able to demonstrate DOX–nanoconjugate stability in vivo and suppress the development of aggressive breast cancer and primary glioma cell lines in vitro. An acidic linker that can be broken under endosomal circumstances

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 323-326 www.ijprajournal.com ISSN: 2456-4494

binds 13 DOX to PMLA-based delivery mechanism before delivering to the target cell. The combination of this medication with hydrazones is proven to be a very successful delivery system for chemotherapy drugs to cancer patients. 13 Because of its versatility, this hydrazone linking application has the potential to have a broad-ranging influence on a large range of disorders. The peptide conjugate's drug release behaviour was examined by Jin et al. to add to the previous study's findings and to better understand the possible contexts in which these hydrazones may be employed. Monitoring the AP2H-hydrazone-DOX degradation using high-performance liquid chromatography (HPLC) and using four different buffer solutions allowed us to plot the DOX release with time. 14 To get to an 80 percent DOX release rate at pH5.0, which is close to the pH of the endolysosomal cell environment, it takes 25 hours. AP2Hhydrazone-chromatographic DOX's peak reduced as incubation time extended at pH 5.0. pH-sensitive hydrazone linker cleavage occurs at pH 5.0 or below, according to this data. Figure 2 demonstrates that the discharge of DOX was extremely efficient and around 80% after 40 hours at varying pH levels. At a physiological pH of 7.4, however, only around 10% of DOX was released after 40 hours. DOX's release profile was similar at both pH 5.0 and 7.4. 14 Dox nanoconjugates are stable under physiologically neutral circumstances, according to these investigations (pH 7.4). 2,13,14 hydrazone linkers have also been employed in conjunction with nanoparticles for cancer-targeted medication release, 2 Chemotherapy's poor therapeutic advantages in glioma patients are owing in part to its failure to pass the blood-brain-blood bloodblood–brain barrier (BBB) due to tight junctions. Nanoparticles may operate as drug delivery vehicles and target the BBB seleutilizingbyutilising Au-NPs coated with targeting antibodies and peptides. 2 Transactivator of transcriptional (TAT) and DOX were functionalized onto Au-NPs, specifically the cell-penetrating peptides. DOX coupled to TAT-Au-NP and freedom were used as controls in an in vitro experiment. 2 Using a glioma-infected mouse model



Figure 2. Release kinetics of DOX from nanoconjugate at pH 5.0 (red) and pH 7.4 (green) at 37 °C.[13] Copyright 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

International Journal of Pharmaceutical Research and Applications
Volume 7, Issue 3 May-June 2022, pp: 323-326 www.ijprajournal.com ISSN: 2456-4494

intravenously infused TAT-Au-NP-DOX into the patient's cells. Images of the tumor obtained using transmission electron microscopy (TEM) after 24 hours showed where the Au-NPs had been able to move. Moreover over a month after treatment, animals given TAT-Au-NP-Dox survived an additional 44 days compared to those given DOX alone. Au-NPs were able to penetrate glioma cell lysosomes and disperse themselves over the membrane as seen by TEM pictures. TAT-Au-NP-DOX particles were discovered to have no cytotoxicity, proving their safety and effectiveness for cancer treatment. 2 To detect and target the tumor marker lysosomal proteins transmembrane 4 betas, AP2H (IHGHHIISVG) has been employed for cancer.14

REFERENCES

[1]. De Jong, W. H.; Borm, P. J. Drug Delivery and Nanoparticles:Applications and Hazards. Int. J. Nanomed. **2008**, 3, 133–149.
[2]. Cheng, Y.; Dai, Q.; Morshed, R.; et al. Blood-Brain BarrierPermeable Gold Nanoparticles: An Efficient DeliveryPlatform for Enhanced Malignant Glioma Therapy andImaging. Small **2014**, 10, 5137–5150.
[3]. Rollas, S.; Küçükgüzel, Ş. G. Biological Activities ofHydrazone Derivatives. Molecules **2007**, 12, 1910–1939.
[4]. Kolmel, D; Tool, E. Oximes and Hydrazones in Biconjugation:Mechanism and Catalysis. Chem Rev. **2017**, 117, 10358–10376.
[5]. Jeselnik, R.; Varma, S.; Polanc, M.; et al. Solid-StateSynthesis of Heterocyclic Hydrazones Using Microwavesunder Catalyst-Free Conditions. Green Chem. **2002**, 4,35–38.
[6]. Alam, G.; Verma, M.; Shaquiquzzaman, A.; et al. A ReviewExploring Biological Activities of Hydrazones. J. Pharm.Bioallied Sci. **2014**, 6, 69.
[7]. Li, L.; Peng, J.; Zhou, W.; et al. Potent Hydrazone DerivativesTargeting Esophageal Cancer Cells. Eur. J. Med. Chem. **2018**,148, 359–371.
[8]. Hussain, I.; Ali, A. Exploring the Pharmacological Activitiesof Hydrazone Derivatives: A Review. J. Phytochem. Biochem.**2017**, 1, 1–5.
[9]. Sonawane, S.; Kalhapure, R.; Govender, T. HydrazoneLinkages in pH Responsive Drug Delivery Systems. Eur. J.Pharm. Sci. **2017**, 99, 45–65.
[10]. Crisalli, P.; Kool, E. Importance of Ortho Proton Donorsin Catalysis of Hydrazone Formation. Org. Lett. **2013**, 15,1646–1649.
[11]. Ye, W.; Zhao, Y.; Li, H.; et al. Doxorubicin-Poly (EthyleneGlycol)-Alendronate Self-Assembled Micelles for TargetedBone Metastatic Cancer. Nat. Res. J. **2015**, 5, 14614.
[12]. Banerjee, S.; Mondal, S.; Chakraborty, W.; et al. Syntheses,X-Ray Crystal Structures, DNA Binding, Oxidative Cleavageand Antimicrobial Studies of Two Cu (II) HydrazoneComplexes. Polyhedron **2009**, 28, 2785–2793.
[13]. Patil, R.; Portilla-Arias, J.; Ding, H.; et al. Cellular Deliveryof Doxorubicin via pH-Controlled Hydrazone Linkage UsingMultifunctional Nano Vehicle Based on Poly (β-L-Malic
[14]. Acid). Int. J. Mol. Sci. **2012**, 13, 11681–11693.
[15]. Jin, Y.; Huang, Y.; Yang, H.; et al. A Peptide Based pH-SensitiveDrug Delivery System for Targeted Ablation of CancerCells. Chem. Commun. **2015**, 51, 14454–14457.